Base de dados : MEDLINE
Pesquisa : C04.557.470.565 [Categoria DeCS]
Referências encontradas : 532 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 54 ir para página                         

  1 / 532 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29362916
[Au] Autor:Tanaka T; Voigt MD
[Ad] Endereço:Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA, USA. tomohiro-tanaka@uiowa.edu.
[Ti] Título:Decision tree analysis to stratify risk of de novo non-melanoma skin cancer following liver transplantation.
[So] Source:J Cancer Res Clin Oncol;144(3):607-615, 2018 Mar.
[Is] ISSN:1432-1335
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Non-melanoma skin cancer (NMSC) is the most common de novo malignancy in liver transplant (LT) recipients; it behaves more aggressively and it increases mortality. We used decision tree analysis to develop a tool to stratify and quantify risk of NMSC in LT recipients. METHODS: We performed Cox regression analysis to identify which predictive variables to enter into the decision tree analysis. Data were from the Organ Procurement Transplant Network (OPTN) STAR files of September 2016 (n = 102984). RESULTS: NMSC developed in 4556 of the 105984 recipients, a mean of 5.6 years after transplant. The 5/10/20-year rates of NMSC were 2.9/6.3/13.5%, respectively. Cox regression identified male gender, Caucasian race, age, body mass index (BMI) at LT, and sirolimus use as key predictive or protective factors for NMSC. These factors were entered into a decision tree analysis. The final tree stratified non-Caucasians as low risk (0.8%), and Caucasian males > 47 years, BMI < 40 who did not receive sirolimus, as high risk (7.3% cumulative incidence of NMSC). The predictions in the derivation set were almost identical to those in the validation set (r = 0.971, p < 0.0001). Cumulative incidence of NMSC in low, moderate and high risk groups at 5/10/20 year was 0.5/1.2/3.3, 2.1/4.8/11.7 and 5.6/11.6/23.1% (p < 0.0001). CONCLUSIONS: The decision tree model accurately stratifies the risk of developing NMSC in the long-term after LT.
[Mh] Termos MeSH primário: Técnicas de Apoio para a Decisão
Árvores de Decisões
Transplante de Fígado/efeitos adversos
Neoplasias Cutâneas/etiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Feminino
Seres Humanos
Imunossupressores/uso terapêutico
Incidência
Transplante de Fígado/estatística & dados numéricos
Masculino
Meia-Idade
Neoplasia de Células Basais/epidemiologia
Neoplasia de Células Basais/etiologia
Neoplasias de Células Escamosas/epidemiologia
Neoplasias de Células Escamosas/etiologia
Medição de Risco
Fatores de Risco
Neoplasias Cutâneas/epidemiologia
Condicionamento Pré-Transplante/efeitos adversos
Condicionamento Pré-Transplante/estatística & dados numéricos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunosuppressive Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE
[do] DOI:10.1007/s00432-018-2589-5


  2 / 532 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28795417
[Au] Autor:Henry G; Malewska A; Mauck R; Gahan J; Hutchinson R; Torrealba J; Francis F; Roehrborn C; Strand D
[Ad] Endereço:Department of Urology, UT Southwestern Medical Center, Dallas, Texas.
[Ti] Título:Molecular pathogenesis of human prostate basal cell hyperplasia.
[So] Source:Prostate;77(13):1344-1355, 2017 May.
[Is] ISSN:1097-0045
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Understanding the molecular pathogenesis of distinct phenotypes in human benign prostatic hyperplasia (BPH) is essential to improving therapeutic intervention. Current therapies target smooth muscle and luminal epithelia for relief of lower urinary tract symptoms (LUTS) due to BPH, but basal cell hyperplasia (BCH) remains untargeted. The incidence of has been reported at 8-10%, but a molecular and cellular characterization has not been performed on this phenotype. METHODS: Using freshly digested tissue from surgical specimens, we performed RNA-seq analysis of flow cytometry-purified basal epithelia from 3 patients with and 4 patients without a majority BCH phenotype. qPCR was performed on 28 genes identified as significant from 13 non-BCH and 7 BCH specimens to confirm transcriptomic analysis. IHC was performed on several non-BCH and BCH specimens for 3 proteins identified as significant by transcriptomic analysis. RESULTS: A total of 141 human BPH specimens were analyzed for the presence of BCH. Clinical characteristics of non-BCH and BCH cohorts revealed no significant differences in age, PSA, prostate volume, medical treatment, or comorbidities. Quantitation of cellular subsets by flow cytometry in 11 BCH patients vs. 11 non-BCH patients demonstrated a significant increase in the ratio of basal to luminal epithelia in patients with BCH (P <0.05), but no significant differences in the total number of leukocytes. RNA-seq data from flow cytometry isolated basal epithelia from patients with and without BCH were subjected to gene set enrichment analysis of differentially expressed genes, which revealed increased expression of members of the epidermal differentiation complex. Transcriptomic data were complemented by immunohistochemistry for members of the epidermal differentiation complex, revealing a morphological similarity to other stratified squamous epithelial layers. CONCLUSIONS: Increased expression of epidermal differentiation complex members and altered epithelial stratification resembles the progression of other metaplastic diseases. These data provide insight into the plasticity of the human prostate epithelium and suggest a classification of basal cell hyperplasia as a metaplasia.
[Mh] Termos MeSH primário: Células Epiteliais/patologia
Integrina alfa6/genética
Proteínas de Membrana/genética
Neoplasia de Células Basais
Próstata/patologia
Hiperplasia Prostática
[Mh] Termos MeSH secundário: Idoso
Gerenciamento Clínico
Progressão da Doença
Perfilação da Expressão Gênica/métodos
Seres Humanos
Imuno-Histoquímica
Masculino
Metaplasia/genética
Metaplasia/patologia
Meia-Idade
Neoplasia de Células Basais/tratamento farmacológico
Neoplasia de Células Basais/genética
Neoplasia de Células Basais/patologia
Tamanho do Órgão
Hiperplasia Prostática/tratamento farmacológico
Hiperplasia Prostática/genética
Hiperplasia Prostática/patologia
Análise de Sequência de RNA/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CKAP4 protein, human); 0 (Integrin alpha6); 0 (Membrane Proteins)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170921
[Lr] Data última revisão:
170921
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170811
[St] Status:MEDLINE
[do] DOI:10.1002/pros.23394


  3 / 532 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28170369
[Au] Autor:Liu Y; Wu C; Zhu T; Sun W
[Ad] Endereço:Laboratory of Molecular Genetics, School of Medicine, Nankai University, Tianjin, China (mainland).
[Ti] Título:LMO2 Enhances Lamellipodia/Filopodia Formation in Basal-Type Breast Cancer Cells by Mediating ARP3-Profilin1 Interaction.
[So] Source:Med Sci Monit;23:695-703, 2017 Feb 07.
[Is] ISSN:1643-3750
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND The human LMO2 gene was first cloned from an acute T lymphocytic leukemia patient; it is primarily expressed in hematopoietic and vascular endothelial systems, and functions as a pivotal transcriptional regulator during embryonic hematopoiesis and angiogenesis. However, some recent reports indicated that LMO2 is widely expressed in many tissues and tumors, predominantly in cytoplasm, and revealed complicated functions on tumor behaviors in a variety of cancer types. As an adaptor molecule, binding partners and function details of LMO2 in these solid tumors need to be further investigated. MATERIAL AND METHODS In this study, we used yeast two-hybrid method to screen potential LMO2 interacting partners, MBP-pulldown, and co-immunoprecipitation assay to confirm protein-protein interactions, and confocal microscopy to reveal the subcellular localization of relevant proteins and actin cytoskeleton changes in relevant cells. RESULTS We found that ARP3 and profilin1 were 2 binding partners of LMO2, primarily in cytoplasm. LMO2. Functionally, LMO2 mediated the assembly of a complex including ARP3, profilin1, and actin monomer, increased actin monomer binding to profilin1, and promoted lamellipodia/filopodia formation in basal-type breast cancer cells. CONCLUSIONS Our data indicate a novel functional mechanism of LMO2 in facilitating the delivery of actin monomers to the branched microfilament and increasing lamellipodia/filopodia formation in basal-type breast cancer cells, suggesting a cancer-promoting role of LMO2 in a subtype-dependent manner and its potential as a subtype-specific biomarker for clinical treatment of breast cancers.
[Mh] Termos MeSH primário: Proteína 3 Relacionada a Actina/metabolismo
Proteínas Adaptadoras de Transdução de Sinal/metabolismo
Neoplasias da Mama/patologia
Proteínas com Domínio LIM/metabolismo
Neoplasia de Células Basais/patologia
Profilinas/metabolismo
Proteínas Proto-Oncogênicas/metabolismo
Pseudópodes/metabolismo
[Mh] Termos MeSH secundário: Proteína 3 Relacionada a Actina/genética
Actinas/metabolismo
Proteínas Adaptadoras de Transdução de Sinal/genética
Neoplasias da Mama/genética
Neoplasias da Mama/metabolismo
Linhagem Celular Tumoral
Citoplasma/metabolismo
Feminino
Células HEK293
Seres Humanos
Proteínas com Domínio LIM/genética
Neoplasia de Células Basais/genética
Neoplasia de Células Basais/metabolismo
Profilinas/genética
Ligação Proteica
Proteínas Proto-Oncogênicas/genética
Pseudópodes/genética
Pseudópodes/patologia
Transfecção
Técnicas do Sistema de Duplo-Híbrido
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ACTR3 protein, human); 0 (Actin-Related Protein 3); 0 (Actins); 0 (Adaptor Proteins, Signal Transducing); 0 (LIM Domain Proteins); 0 (LMO2 protein, human); 0 (PFN1 protein, human); 0 (Profilins); 0 (Proto-Oncogene Proteins)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170612
[Lr] Data última revisão:
170612
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170208
[St] Status:MEDLINE


  4 / 532 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28108512
[Au] Autor:Choy L; Hagenbeek TJ; Solon M; French D; Finkle D; Shelton A; Venook R; Brauer MJ; Siebel CW
[Ad] Endereço:Department of Discovery Oncology, Genentech, Inc., South San Francisco, California.
[Ti] Título:Constitutive NOTCH3 Signaling Promotes the Growth of Basal Breast Cancers.
[So] Source:Cancer Res;77(6):1439-1452, 2017 Mar 15.
[Is] ISSN:1538-7445
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Notch ligands signal through one of four receptors on neighboring cells to mediate cell-cell communication and control cell fate, proliferation, and survival. Although aberrant Notch activation has been implicated in numerous malignancies, including breast cancer, the importance of individual receptors in distinct breast cancer subtypes and the mechanisms of receptor activation remain unclear. Using a novel antibody to detect active NOTCH3, we report here that NOTCH3 signals constitutively in a panel of basal breast cancer cell lines and in more than one third of basal tumors. Selective inhibition of individual ligands revealed that this signal does not require canonical ligand induction. A NOTCH3 antagonist antibody inhibited growth of basal lines, whereas a NOTCH3 agonist antibody enhanced the transformed phenotype and in tumor xenografts. Transcriptomic analyses generated a Notch gene signature that included Notch pathway components, the oncogene , and the mammary stem cell regulator This signature drove clustering of breast cancer cell lines and tumors into the common subtypes and correlated with the basal classification. Our results highlight an unexpected ligand-independent induction mechanism and suggest that constitutive NOTCH3 signaling can drive an oncogenic program in a subset of basal breast cancers. .
[Mh] Termos MeSH primário: Biomarcadores Tumorais/metabolismo
Neoplasias da Mama/patologia
Proliferação Celular
Neoplasia de Células Basais/patologia
Receptor Notch3/metabolismo
[Mh] Termos MeSH secundário: Animais
Apoptose
Neoplasias da Mama/metabolismo
Feminino
Seres Humanos
Camundongos
Camundongos Knockout
Camundongos SCID
Neoplasia de Células Basais/metabolismo
Receptor Notch3/genética
Transdução de Sinais
Células Tumorais Cultivadas
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Receptor, Notch3)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170122
[St] Status:MEDLINE
[do] DOI:10.1158/0008-5472.CAN-16-1022


  5 / 532 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27504964
[Au] Autor:Garcia-Garcia SC; Villarreal-Martinez A; Guerrero-Gonzalez GA; Miranda-Maldonado I; Ocampo-Candiani J
[Ad] Endereço:Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México.
[Ti] Título:Dermoscopy of trichofolliculoma: a rare hair follicle hamartoma.
[So] Source:J Eur Acad Dermatol Venereol;31(2):e123-e124, 2017 Feb.
[Is] ISSN:1468-3083
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Dermoscopia
Cisto Folicular/diagnóstico
Hamartoma/diagnóstico
Neoplasia de Células Basais/diagnóstico
Neoplasias Cutâneas/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Diagnóstico Diferencial
Cisto Folicular/patologia
Hamartoma/patologia
Seres Humanos
Masculino
Neoplasia de Células Basais/patologia
Neoplasias Cutâneas/patologia
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170515
[Lr] Data última revisão:
170515
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160810
[St] Status:MEDLINE
[do] DOI:10.1111/jdv.13870


  6 / 532 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27097063
[Au] Autor:Al-Ghadeer H; Edward DP
[Ad] Endereço:*Emergency Department, and †Glaucoma Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
[Ti] Título:Congenital Sebaceous Trichofolliculoma of the Upper Eyelid.
[So] Source:Ophthal Plast Reconstr Surg;33(3S Suppl 1):S60-S61, 2017 May/Jun.
[Is] ISSN:1537-2677
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A 6-year-old male presented with a protruding hair emerging from a temporally located nodule on his left upper eyelid 5mm above the eyelid margin since birth. The lesion was excised and sent to histopathology. The features were consistent with congenital sebaceous trichofolliculoma, a rare hamartomatous skin lesion.
[Mh] Termos MeSH primário: Neoplasias Palpebrais/diagnóstico
Pálpebras/patologia
Cisto Folicular/diagnóstico
Neoplasia de Células Basais/diagnóstico
Neoplasias Cutâneas/diagnóstico
[Mh] Termos MeSH secundário: Criança
Diagnóstico Diferencial
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170630
[Lr] Data última revisão:
170630
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160421
[St] Status:MEDLINE
[do] DOI:10.1097/IOP.0000000000000698


  7 / 532 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27923045
[Au] Autor:Hoadley KA; Siegel MB; Kanchi KL; Miller CA; Ding L; Zhao W; He X; Parker JS; Wendl MC; Fulton RS; Demeter RT; Wilson RK; Carey LA; Perou CM; Mardis ER
[Ad] Endereço:Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
[Ti] Título:Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases.
[So] Source:PLoS Med;13(12):e1002174, 2016 Dec.
[Is] ISSN:1549-1676
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Metastasis is the main cause of cancer patient deaths and remains a poorly characterized process. It is still unclear when in tumor progression the ability to metastasize arises and whether this ability is inherent to the primary tumor or is acquired well after primary tumor formation. Next-generation sequencing and analytical methods to define clonal heterogeneity provide a means for identifying genetic events and the temporal relationships between these events in the primary and metastatic tumors within an individual. METHODS AND FINDINGS: We performed DNA whole genome and mRNA sequencing on two primary tumors, each with either four or five distinct tissue site-specific metastases, from two individuals with triple-negative/basal-like breast cancers. As evidenced by their case histories, each patient had an aggressive disease course with abbreviated survival. In each patient, the overall gene expression signatures, DNA copy number patterns, and somatic mutation patterns were highly similar across each primary tumor and its associated metastases. Almost every mutation found in the primary was found in a metastasis (for the two patients, 52/54 and 75/75). Many of these mutations were found in every tumor (11/54 and 65/75, respectively). In addition, each metastasis had fewer metastatic-specific events and shared at least 50% of its somatic mutation repertoire with the primary tumor, and all samples from each patient grouped together by gene expression clustering analysis. TP53 was the only mutated gene in common between both patients and was present in every tumor in this study. Strikingly, each metastasis resulted from multiclonal seeding instead of from a single cell of origin, and few of the new mutations, present only in the metastases, were expressed in mRNAs. Because of the clinical differences between these two patients and the small sample size of our study, the generalizability of these findings will need to be further examined in larger cohorts of patients. CONCLUSIONS: Our findings suggest that multiclonal seeding may be common amongst basal-like breast cancers. In these two patients, mutations and DNA copy number changes in the primary tumors appear to have had a biologic impact on metastatic potential, whereas mutations arising in the metastases were much more likely to be passengers.
[Mh] Termos MeSH primário: Neoplasias da Mama/genética
Progressão da Doença
Neoplasia de Células Basais/genética
[Mh] Termos MeSH secundário: Idoso
Neoplasias da Mama/secundário
Feminino
Genômica
Seres Humanos
Meia-Idade
Mutação
Neoplasia de Células Basais/secundário
Estudos Retrospectivos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170909
[Lr] Data última revisão:
170909
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161207
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pmed.1002174


  8 / 532 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27848425
[Au] Autor:Berry L
[Ti] Título:Skin cancer.
[So] Source:Nurs Stand;31(11):15, 2016 Nov 09.
[Is] ISSN:2047-9018
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Essential facts Skin cancer can be split into 2 groups: malignant melanoma, which can be fatal; and non-melanoma, such as squamous cell carcinoma and basal cell carcinomas, which are rarely lethal. In 2013 there were 14,509 new cases of malignant melanoma in the UK and, in 2014, 2,459 people died from the disease. Non-melanoma skin cancers are more common; 72,100 new cases were diagnosed in the UK in 2013.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas
Melanoma
Neoplasia de Células Basais
Neoplasias Cutâneas
[Mh] Termos MeSH secundário: Carcinoma de Células Escamosas/diagnóstico
Carcinoma de Células Escamosas/terapia
Seres Humanos
Melanoma/diagnóstico
Melanoma/terapia
Neoplasia de Células Basais/diagnóstico
Neoplasia de Células Basais/terapia
Neoplasias Cutâneas/diagnóstico
Neoplasias Cutâneas/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170419
[Lr] Data última revisão:
170419
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:161117
[St] Status:MEDLINE


  9 / 532 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27612592
[Au] Autor:Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
[Ad] Endereço:Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
[Ti] Título:Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
[So] Source:EBioMedicine;12:105-117, 2016 Oct.
[Is] ISSN:2352-3964
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: It has been suggested that bladder cancer can be divided into two molecular subtypes referred to as luminal and basal with distinct clinical behaviors and sensitivities to chemotherapy. We aimed to validate these subtypes in several clinical cohorts and identify signature immunohistochemical markers that would permit simple and cost-effective classification of the disease in primary care centers. METHODS: We analyzed genomic expression profiles of bladder cancer in three cohorts of fresh frozen tumor samples: MD Anderson (n=132), Lund (n=308), and The Cancer Genome Atlas (TCGA) (n=408) to validate the expression signatures of luminal and basal subtypes and relate them to clinical follow-up data. We also used an MD Anderson cohort of archival bladder tumor samples (n=89) and a parallel tissue microarray to identify immunohistochemical markers that permitted the molecular classification of bladder cancer. FINDINGS: Bladder cancers could be assigned to two candidate intrinsic molecular subtypes referred to here as luminal and basal in all of the datasets analyzed. Luminal tumors were characterized by the expression signature similar to the intermediate/superficial layers of normal urothelium. They showed the upregulation of PPARγ target genes and the enrichment for FGFR3, ELF3, CDKN1A, and TSC1 mutations. In addition, luminal tumors were characterized by the overexpression of E-Cadherin, HER2/3, Rab-25, and Src. Basal tumors showed the expression signature similar to the basal layer of normal urothelium. They showed the upregulation of p63 target genes, the enrichment for TP53 and RB1 mutations, and overexpression of CD49, Cyclin B1, and EGFR. Survival analyses showed that the muscle-invasive basal bladder cancers were more aggressive when compared to luminal cancers. The immunohistochemical expressions of only two markers, luminal (GATA3) and basal (KRT5/6), were sufficient to identify the molecular subtypes of bladder cancer with over 90% accuracy. INTERPRETATION: The molecular subtypes of bladder cancer have distinct clinical behaviors and sensitivities to chemotherapy, and a simple two-marker immunohistochemical classifier can be used for prognostic and therapeutic stratification. FUNDING: U.S. National Cancer Institute and National Institute of Health.
[Mh] Termos MeSH primário: Biomarcadores Tumorais
Neoplasia de Células Basais/diagnóstico
Neoplasia de Células Basais/metabolismo
Neoplasias da Bexiga Urinária/diagnóstico
Neoplasias da Bexiga Urinária/metabolismo
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Análise por Conglomerados
Estudos de Coortes
Feminino
Perfilação da Expressão Gênica
Seres Humanos
Imuno-Histoquímica
Masculino
Meia-Idade
Mutação
Invasividade Neoplásica
Estadiamento de Neoplasias
Neoplasia de Células Basais/genética
Neoplasia de Células Basais/mortalidade
Prognóstico
Análise de Sobrevida
Análise Serial de Tecidos
Neoplasias da Bexiga Urinária/genética
Neoplasias da Bexiga Urinária/mortalidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171009
[Lr] Data última revisão:
171009
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160911
[St] Status:MEDLINE


  10 / 532 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27238744
[Au] Autor:Lozano-Masdemont B; Rodríguez-Soria VJ; Gómez-Recuero-Muñoz L; Parra-Blanco V
[Ad] Endereço:Servicio de Dermatología, Hospital General Universitario Gregorio Marañón, Madrid, España. Electronic address: belenmasdemont@gmail.com.
[Ti] Título:Trichogerminoma: A Neoplasm With Follicular Differentiation and a Characteristic Morphology.
[Ti] Título:Tricogerminoma: una neoplasia con diferenciación folicular y una morfología característica..
[So] Source:Actas Dermosifiliogr;107(9):789-791, 2016 Nov.
[Is] ISSN:1578-2190
[Cp] País de publicação:Spain
[La] Idioma:eng; spa
[Mh] Termos MeSH primário: Neoplasia de Células Basais/patologia
Neoplasias Cutâneas/patologia
[Mh] Termos MeSH secundário: Idoso
Biomarcadores Tumorais/análise
Biópsia
Diferenciação Celular
Diagnóstico Diferencial
Cisto Epidérmico/diagnóstico
Seres Humanos
Queratinas/análise
Masculino
Neoplasia de Células Basais/classificação
Neoplasia de Células Basais/diagnóstico
Neoplasias Cutâneas/diagnóstico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 68238-35-7 (Keratins)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160531
[St] Status:MEDLINE



página 1 de 54 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde